Drug Profile
Autologous T-cell vaccine - Acer Therapeutics
Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Shanghai Institutes for Biological Sciences
- Class
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
- 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics
- 17 Sep 2009 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in China (SC)